Prohost Biotech – Exclusive Biotech Research

Exclusive Market Insight

& Scientific analysis

  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Menu
  • Impacting News
  • News & Comments
  • Today’s Highlights
  • Trick or Trade
  • Prohost Letters
  • Login / Register
    • Login
    • Register
  • Contact Us
  • Impacting News
  • News & Comments
  • Today’s Highlights
  • Trick or Trade
  • Prohost Letters
  • Login / Register
    • Login
    • Register
  • Contact Us

Helping Your Pets to be Healthy and Live Longer

August 12, 2025 0
Boehringer Ingelheim The following is not for investors but for people who love pets and want them to be healthy and live longer. Those who care about animals should know what’s going on in the highly regarded veterinary research and practice, and the next generation of biomedical researchers. Recently, a posted text informed that Boehringer Ingelheim has celebrated the next …

Praxis Precision Medicines Radiant Study with Vormatrigine

ARS Pharmaceuticals Announces FDA Approval of neffy® for Type I...

Nuvig Therapeutics Announces $161 Million Series B Financing, Plus Its...

Iterum Therapeutics Receives US FDA Approval of ORLYNVAH™ for the...

The United States FDA Approved Astellas’ product VYLOY in Combination...

U.S. FDA Approves AbbVie’s VYALEV™ for Adults Living with Advanced...

Novo Nordisk Launches New Initiative To Prevent Childhood Obesity In...

The FDA Approved IntraBio Product AQNEURSA As the only treatment...

Jeune Aesthetics: Reversing the Biology of Aging Skin to Meet...

Galderma Receives U.S. FDA Approval for Nemluvio® for Adult Patients...

SCG Cell Therapy: FDA Approved IND Application of Product SCG142...

Mitsubishi Tanabe Pharma America Announced the Presentations of its ND0612...

 AstraZeneca: The U.S. FDA Approved IMFINZI in Combination with Carboplatin...

Regeneron: Improved Hearing to Normal Levels in a Child with...

INmune Bio Inc. Update on Two Alzheimer Disease Patients Who...

Cerevel Therapeutics Announces Positive Results for Tavapadon in Phase 3...

Italfarmaco Received FDA Approval for Duvyzat™ for the Treatment of...

Abbott Laboratories Launches a New PROTALITY™ Brand to Maintain the...

Sanofi to Acquire Inhibrx, Inc.

Impacting News

FDA New Approvals of COVID-19 Vaccines

August 28, 2025 0
Approved COVID-19 Vaccines As of late August 2025, the U.S. Food and Drug Administration (FDA) has …

How to Bring Undervalued Stocks to Their Real Values and What About Intellia Therapeutics Stock?

August 26, 2025 0
One bad market day or more can help investors make it a good biotech market day. …

Ionis Pharmaceuticals DAWNZERA™ Granted US FDA Approval as First and Only RNA-Targeted Prophylactic Treatment for Hereditary Angioedema  

August 23, 2025 0
Ionis Pharmaceuticals Ionis Pharmaceuticals (IONS) announced  that the U.S. FDA has approved DAWNZERA™ (donidalorsen) for prophylaxis …

Rhythm Pharmaceuticals Announces the FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity

August 21, 2025 0
Rhythm Pharmaceuticals in the NEWS Rhythm Pharmaceuticals, Inc. (RYTM) announced that the U.S. FDA has accepted …

Akero Therapeutics Q2 Financial and Study Results

August 11, 2025 0
Akero Therapeutics Akero Therapeutics (AKRO) reported its Q22025 financial results for the period ending June 30, …

Gilead Sciences Announced Its Q2 2025 Financial Results Yesterday

August 8, 2025 0
Gilead Sciences Reached Prohost Biotech's Target Gilead Sciences (GILD) reached our target of $120 today. Some …

Trick or Trade

Alnylam’s Presentation In Early September

August 28, 2025 0
Alnylam Pharmaceuticals Presentations In early September 2025, Alnylam Pharmaceuticals (ALNY) will present two investor conferences. The …

Klotho Neurosciences to Expand Development Programs Beyond Neurology

July 28, 2025 0
Klotho Neurosciences to Pursue Technologies to Improve Brain Function, Muscle Strength, Bone Health, and Other Longevity …

Question & Answer About Kiniksa Pharmaceuticals

July 17, 2025 0
Q & A: Kiniksa Pharmaceuticals Q: Do you have any recent news from Kiniksa Pharmaceuticals?  A: …

Why We Believe That BioNTech Will Have A Great Future

June 18, 2025 0
Biotechnology and biopharmaceutical firms were doing great until the day the COVID-19 pandemic changed the lives …

Why Prohost Decided To Pick Soleno Therapeutics For Investment

June 5, 2025 0
Soleno Therapeutics Soleno Therapeutics (SLNO) announced that’s Marketing Authorization Application (MAA) seeking regulatory approval of Diazoxide …

Answering Questions About Vera Therapeutics

May 19, 2025 0
Vera Therapeutics Q: What did Vera Therapeutics announce on May 6th that is more than what …

Today’s Highlights

BioArctic and Novartis Sign a Collaboration and License Agreement Using BrainTransporter™

August 27, 2025 0
BioArtic AB & Novartis Sign Agreement Stockholm, Sweden, August 26, 2025 – BioArctic AB (publ) (Nasdaq …

Precigen Announces Full FDA Approval of PAPZIMEOS, the Only Currently Approved  Treatment for Adults with Recurrent Respiratory Papillomatosis

August 15, 2025 0
Precigen in the NEWS Precigen (PGEN) announced that the United States (FDA) has approved the product  PAPZIMEOS™ (zopapogene imadenovec-drba) …

Approval of BRINSUPRI™ for the Treatment of Non-Cystic Fibrosis Bronchiectasis

August 13, 2025 0
Insmed Incorporated Today, investors must have realized the upward movement prices of the Viking Therapeutics (VKTX) …

How Alnylam Pharmaceuticals Made Our Day Today and More

July 31, 2025 0
Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress The Financial Results …

GSK Announces the Linked by Lupus: Optimal Care Initiative to Help Support Individuals with Lupus in the US

July 28, 2025 0
GSK in the NEWS Today, GSK plc (GSK) announced the launch of the Linked by Lupus: …

AstraZeneca’s Product Gefurulimab Demonstrated Daily Living of Adults with Generalised Myasthenia Gravis in PREVAIL Phase III Trial

July 24, 2025 0
AstraZeneca's Product Gefurulimab Once-weekly self-administered subcutaneous C5 inhibitor showed statistically significant and clinically meaningful reduction in …

Latest Articlesddd

Alnylam’s Presentation In Early September

August 28, 2025 0
Alnylam Pharmaceuticals Presentations In early September 2025, Alnylam Pharmaceuticals (ALNY) will present two investor conferences. The …

FDA New Approvals of COVID-19 Vaccines

August 28, 2025 0
Approved COVID-19 Vaccines As of late August 2025, the U.S. Food and Drug Administration (FDA) has …

BioArctic and Novartis Sign a Collaboration and License Agreement Using BrainTransporter™

August 27, 2025 0
BioArtic AB & Novartis Sign Agreement Stockholm, Sweden, August 26, 2025 – BioArctic AB (publ) (Nasdaq …

How to Bring Undervalued Stocks to Their Real Values and What About Intellia Therapeutics Stock?

August 26, 2025 0
One bad market day or more can help investors make it a good biotech market day. …

Ionis Pharmaceuticals DAWNZERA™ Granted US FDA Approval as First and Only RNA-Targeted Prophylactic Treatment for Hereditary Angioedema  

August 23, 2025 0
Ionis Pharmaceuticals Ionis Pharmaceuticals (IONS) announced  that the U.S. FDA has approved DAWNZERA™ (donidalorsen) for prophylaxis …

Rhythm Pharmaceuticals Announces the FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity

August 21, 2025 0
Rhythm Pharmaceuticals in the NEWS Rhythm Pharmaceuticals, Inc. (RYTM) announced that the U.S. FDA has accepted …

Precigen Announces Full FDA Approval of PAPZIMEOS, the Only Currently Approved  Treatment for Adults with Recurrent Respiratory Papillomatosis

August 15, 2025 0
Precigen in the NEWS Precigen (PGEN) announced that the United States (FDA) has approved the product  PAPZIMEOS™ (zopapogene imadenovec-drba) …

Approval of BRINSUPRI™ for the Treatment of Non-Cystic Fibrosis Bronchiectasis

August 13, 2025 0
Insmed Incorporated Today, investors must have realized the upward movement prices of the Viking Therapeutics (VKTX) …

Helping Your Pets to be Healthy and Live Longer

August 12, 2025 0
Boehringer Ingelheim The following is not for investors but for people who love pets and want …

Akero Therapeutics Q2 Financial and Study Results

August 11, 2025 0
Akero Therapeutics Akero Therapeutics (AKRO) reported its Q22025 financial results for the period ending June 30, …

Gilead Sciences Announced Its Q2 2025 Financial Results Yesterday

August 8, 2025 0
Gilead Sciences Reached Prohost Biotech's Target Gilead Sciences (GILD) reached our target of $120 today. Some …

Praxis Precision Medicines Radiant Study with Vormatrigine

August 5, 2025 0
Praxis Precision Medicines in the NEWS  On Aug. 04, 2025, the biopharmaceutical company Praxis Precision Medicines …

How Alnylam Pharmaceuticals Made Our Day Today and More

July 31, 2025 0
Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress The Financial Results …

AstraZeneca Imfinzi Granted Priority Review and Breakthrough Therapy Designation in US for Patients with Resectable Early-Stage Gastric and Gastroesophageal Junction Cancers

July 30, 2025 0
AstraZeneca Imfinzi Based on MATTERHORN Phase III trial results which demonstrated a statistically significant and clinically …

Klotho Neurosciences to Expand Development Programs Beyond Neurology

July 28, 2025 0
Klotho Neurosciences to Pursue Technologies to Improve Brain Function, Muscle Strength, Bone Health, and Other Longevity …

GSK Announces the Linked by Lupus: Optimal Care Initiative to Help Support Individuals with Lupus in the US

July 28, 2025 0
GSK in the NEWS Today, GSK plc (GSK) announced the launch of the Linked by Lupus: …

Eli Lilly Completes Acquisition of Verve Therapeutics to Advance One-Time Treatments for People with High Cardiovascular Risk

July 25, 2025 0
Eli Lilly Acquired Verve Therapeutics Eli Lilly and Company (LLY) today announced the successful completion of …

AstraZeneca’s Product Gefurulimab Demonstrated Daily Living of Adults with Generalised Myasthenia Gravis in PREVAIL Phase III Trial

July 24, 2025 0
AstraZeneca's Product Gefurulimab Once-weekly self-administered subcutaneous C5 inhibitor showed statistically significant and clinically meaningful reduction in …

AstraZeneca Plans to Invest $50 billion in America for Medicines Manufacturing and R&D Generated in the US  

July 22, 2025 0
AstraZeneca in the NEWS Cornerstone of investment is a proposed new multi-billion dollar drug substance manufacturing …

 Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline

July 21, 2025 0
Axsome Therapeutics Axsome Therapeutics (AXSM) is a biopharmaceutical company leading a new era in the treatment …

Posts pagination

1 2 3 4 … 78 Next

Prohost Letters

Prohost Letter #461 ~ Preventing HIV Infection and Treating Primary Biliary Cholangitis

August 21, 2024 0
Prohost Letter #461 Preventing HIV Infection and Treating Primary Biliary Cholangitis Gilead Sciences Gilead Sciences’ (GILD) …

Prohost Letter #460 ~ Treating IgA Nephropathy

June 1, 2024 0
Prohost Letter #460 Treating IgA Nephropathy Immunoglobulin A (IgA), the antibody of the immune system known …

Prohost Letter #459 ~ NAFLD & NASH

March 3, 2024 0
Prohost Letter #459 ~ NAFLD & NASH NAFLD is Non-Alcoholic Fatty Liver Disease, and NASH is …

Prohost Letter #458 ~ Obesity

December 18, 2023 0
Prohost Letter #458 ~ Obesity Finally, obesity is being recognized as a severe sickness. Indeed, obesity …

Discovering The Root Causes of Diseases

September 15, 2023 0
Prohost Letter #457 Discovering The Root Causes of Diseases   Biotech firms with solid scientific fundamentals …

Treatments for Untreatable Diseases

July 16, 2023 0
Prohost Letter #456 Treatments for Untreatable Diseases The revolution in biotechnology is not meant to offer …

Search ProhostBiotech

Popular Links

Aerie Pharmaceuticals (AERI) Agenus (AGEN) Alnylam Pharmaceuticals (ALNY) Amgen (AMGN) Array BioPharma (ARRY) AstraZeneca Plc (AZN) Bellicum Pharmaceuticals Inc (BLCM) Bristol-Myers Squibb (BMY) Celgene (CELG) Celldex Therapeutics (CLDX) Cellectis (CLLS) Celyad (CYAD) Compugen (CGEN) CRISPR Therapeutics (CRSP) CytomX Therapeutics Inc (CTMX) Editas Medicine Inc (EDIT) Enanta Pharmaceuticals (ENTA) Exelixis (EXEL) Gilead Sciences (GILD) Halozyme Therapeutics (HALO) Illumina (ILMN) ImmunoGen (IMGN) Incyte (INCY) Innoviva (INVA) Intellia Therapeutics (NTLA) Ionis Pharmaceuticals Inc (IONS) Karyopharm Therapeutics Inc (KPTI) Merck (MRK) Moderna Inc (MRNA) Nektar Therapeutics (NKTR) Neurocrine Biosciences (NBIX) Novartis (NVS) Portola Pharmaceuticals Inc (PTLA) PTC Therapeutics (PTCT) Regeneron Pharmaceuticals (REGN) Regenxbio (RGNX) Rhythm Pharmaceuticals Inc (RYTM) Sangamo Therapeutics Inc (SGMO) Sarepta Therapeutics (SRPT) Seagen Inc (SGEN) Spark Therapeutics Theravance Biopharma (TBPH) Vertex Pharmaceuticals (VRTX) Xoma (XOMA)
  • Recent

ProhostBiotech Archive

Sign Up for Weekly Emails

Prohost Biotech – Exclusive Biotech Research Copyright © 2025.
© 2014 Prohost Biotech. All rights reserved.

Privacy Policy | Cancellation Policy | Forward Looking Statement

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.